Hurley Capital’s Iovance Biotherapeutics IOVA Stock Holding History

Hurley Capital’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-1,000	Closed	-$2.73K	–	719
2025 Q4	$2.73K	Hold	1,000	–	–	﹤0.01%	490
2025 Q3	$2.17K	Buy	+1,000	New	+$2.36K	﹤0.01%	510

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ICM

Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

Hurley Capital's IOVA Position: Q1 2026 in Review

Hurley Capital sold out of Iovance Biotherapeutics (IOVA) in Q1 2026, closing a stake of 1,000 shares — an estimated $2.73K sold.

Hurley Capital first reported a position in IOVA in Q3 2025 and held it in 2 quarters. The position peaked at $2.73K in Q4 2025. 286 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

Hurley Capital reported no remaining Iovance Biotherapeutics position as of Q1 2026 after selling out during the quarter.
Hurley Capital sold 1,000 Iovance Biotherapeutics shares in Q1 2026, an estimated $2.73K.
Hurley Capital first reported a position in Iovance Biotherapeutics in Q3 2025 and held it in 2 quarters.
Hurley Capital's Iovance Biotherapeutics position peaked at $2.73K in Q4 2025.
286 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on Hurley Capital's 13F filing for Q1 2026, filed 6 May 2026.